Literature DB >> 29275057

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Guoqiao Wang1, Ruth Ann Marrie2, Robert J Fox3, Tuula Tyry4, Stacey S Cofield5, Gary R Cutter5, Amber Salter6.   

Abstract

BACKGROUND: Bladder, bowel, and sexual symptoms are common among persons with multiple sclerosis (MS). We aimed to investigate the frequency and severity of bladder, bowel, and sexual symptoms, the relationships between these symptoms, satisfaction with treatment of these symptoms, and factors associated with symptom severity and treatment satisfaction.
METHODS: In the fall 2010, we surveyed participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry regarding the severity of being bothered by bladder, bowel, and sexual symptoms, their satisfaction of health providers' inquiry and treatment with these symptoms, and whether their quality of life (QOL) had changed with the treatment. Logistic regression was used to evaluate demographic and clinical factors associated with each outcome.
RESULTS: Of 9341 respondents included in the study, 7720 (77.4%) were female and their mean (SD) age was 50.3 (10.5) years. Ninety-one percent of participants were mildly, moderately or severely bothered by bladder, bowel or sexual symptoms. Severity of disability (measured using the Patient Determined Disease Steps), having a relapse in the last 6 months, and catheter use were consistently associated with being bothered (versus not bothered) by each of the three symptoms. Among respondents, 5764 (62.1%) reported that their MS health providers asked about bladder problems, 4523 (51.1%) about bowel problems, and 1890 (20.6%) about sexual problems. At most one-third of participants were completely satisfied with treatment for any of the symptoms. For those who reported how their QOL changed with treatment, 23.0% reported their QOL being better.
CONCLUSION: Bladder, bowel, and sexual problems remain common among persons with MS, and treatment satisfaction is low. Health care providers should consider systematically asking about these symptoms in clinical practice. Greater efforts could be devoted to developing novel, effective therapies to manage these symptoms and thereby improve QOL.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder symptoms; Bowel symptoms; Multiple sclerosis; Quality of life; Sexual symptoms

Mesh:

Year:  2017        PMID: 29275057     DOI: 10.1016/j.msard.2017.12.006

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  4 in total

Review 1.  Is MS affecting the CNS only? Lessons from clinic to myelin pathophysiology.

Authors:  Ellen Oudejans; Antonio Luchicchi; Eva M M Strijbis; Jeroen J G Geurts; Anne-Marie van Dam
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-11-24

2.  Assessment of sexual dysfunction in patients with multiple sclerosis: a perspective from neurologist.

Authors:  Mariana Gaviria-Carrillo; Silvia Juliana Bueno-Florez; Paola Andrea Ortiz-Salas
Journal:  BMC Neurol       Date:  2022-09-29       Impact factor: 2.903

3.  Functional gastrointestinal disorders negatively affect health-related quality of life in MS.

Authors:  Ruth Ann Marrie; Stella Leung; Tuula Tyry; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2019-10

4.  Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.

Authors:  Bisecco Alvino; Fornasiero Arianna; Bianco Assunta; Cortese Antonio; d'Amico Emanuele; Mataluni Giorgia; Sinisi Leonardo; Spitaleri Daniele; Docimo Renato; Maria Chiara Buscarinu; Mirabella Massimiliano; Sebastiano Giuseppe Crisafulli; Zanghì Aurora; Carolina Gabri Nicoletti; Salvetti Marco; Baione Viola; Patti Francesco; Alessandra Girolama Marfia; Sibilia Grazia; Scarano Valentina; Orlando Davide; Stabile Giovanni; Tedeschi Gioacchino; Antonio Gallo
Journal:  J Neurol       Date:  2021-08-04       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.